Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection

Published:2017-05 Issue: Volume:78 Page:1-13
ISSN:0933-3657
Container-title:Artificial Intelligence in Medicine
language:en
Short-container-title:Artificial Intelligence in Medicine

Author:

Leber Andrew,Hontecillas Raquel,Abedi Vida,Tubau-Juni Nuria,Zoccoli-Rodriguez Victoria,Stewart Caroline,Bassaganya-Riera Josep

Publisher

Elsevier BV

Subject

Artificial Intelligence,Medicine (miscellaneous)

Reference53 articles.

1. Burden of Clostridium difficile infection in the United States;Lessa;N Engl J Med,2015

2. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin;Cornely;Clin Infect Dis,2012

3. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada;Pepin;Clin Infect Dis,2005

4. C. difficile infection: changing epidemiology and management paradigms;Vindigni;Clin Transl Gastroenterol,2015

5. Systems modeling of interactions between mucosal immunity and the gut microbiome during Clostridium difficile infection;Leber;PLoS One,2015

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Satisfaction: The Role of Artificial Intelligence in Healthcare;Journal of Health Management;2024-05-15

2. Application of Artificial Intelligence in Infant Movement Classification: A Reliability and Validity Study in Infants Who Were Full-Term and Preterm;Physical Therapy;2024-01-20

3. Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease;Inflammatory Bowel Diseases;2023-11-02

4. Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation;Inflammatory Bowel Diseases;2023-07-12

5. Future of Nanomedicine;The Art of Nanomaterials;2022-09-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3